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Phosphatidylserine (PS) is a potent immunosuppressive
lipid typically segregated to the inner leaflet of the plasma
membrane. PS is externalized on tumor vasculature,
tumor-derived exosomes, and tumor cells in the tumor
microenvironment and externalization is markedly
enhanced by therapy (e.g., radiation, chemotherapy, and/
or androgen deprivation). Externalized PS interacts with
immune cells where it actively promotes immunosup-
pression and tumor progression by expansion of myeloid
derived suppressor cells (MDSCs) and M2-like tumor
associated macrophages (TAMs). Bavituximab is a PS-
targeting antibody that is being evaluated in multiple
late-stage clinical trials in cancer patients. Here we show
that treatment of PC3 tumor-bearing mice with 2aG4,
a murine-version of bavituximab, significantly depleted
M2-likeTAMs and MDSCs and increased the presence of
M1-like TAMs and mature dendritic cells. In addition,
PS blockade markedly altered the cytokine balance in the
tumor microenvironment from immunosuppressive
to immunostimulatory. Furthermore, in the immune-
competent TRAMP mouse prostate tumor model, com-
bination treatment of anti-PS antibody with castration
induced strong tumor-specific T-cell immunity that
resulted in significantly improved tumor free long-term
survival and apparent cures in 35% of the animals, com-
pared to no long-term survivors in groups treated with
either single agent. In vitro studies confirmed that anti-
PS re-polarized TAMs from an M2 to M1-like phenotype
and drove MDSCs to differentiate into M1-like macro-
phages and functional dendritic cells. These data suggest
that PS expression on the external cell surface defines
an upstream immune checkpoint that is primarily
responsible for expansion of MDSCs and M2-like TAMs
in tumors. The results further support that blockade
of the PS signal by bavituximab treatment can reverse
this immune checkpoint suppression and promote thera-
peutically effective anti-tumor immunity.
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